Overview of Doricum (Midazolam)

Property	Description
Active ingredient	Midazolam
Form	Tablet, Solution for Injection/Infusion
Pharmacological Class	Benzodiazepine (Hypnotic, Sedative)
General Purpose	Induces rapid relaxation and sleepiness
Origin	Synthetic compound

Identity and Classification: What Type of Medicine is Doricum (Midazolam)?

Doricum is a brand name for the synthetic compound known generically as Midazolam, which is a powerful, short-acting psychotropic agent belonging to the benzodiazepine pharmacological class. This classification rigorously defines the substance as a central nervous system (CNS) depressant, intended to slow down neural activity. The active constituent is often manufactured as Midazolam hydrochloride for optimal stability, confirming its status as a dedicated single-ingredient product. Midazolam has an established role as a sedative and hypnotic agent, a status clinically recognized for its profound yet transient effect on wakefulness.

General Purpose and Principal Action

Midazolam is fundamentally characterized by its capacity to rapidly induce profound sedation and hypnosis, along with substantial anxiolytic properties. Its primary therapeutic purpose is to achieve swift and effective CNS depression, which is generally useful for quickly promoting a state of deep relaxation or inducing sleepiness in acute, temporary situations. The drug has a fast onset and short duration of action, distinguishing it from longer-acting benzodiazepines. This makes the medicine particularly suitable for situations requiring immediate, powerful, temporary suppression of awareness.

Available Forms: Oral Tablet vs. Solution Preparations

The medicinal entity Midazolam is supplied in several distinct pharmaceutical preparations. While the Doricum brand is typically associated with the tablet dosage form for oral use, the core substance Midazolam is broadly available as a sterile solution for injection or solution for infusion, often packaged in an ampoule. These different preparations allow for multiple routes of administration, including oral, intravenous (IV), and intramuscular (IM), ensuring its short-acting properties can be deployed effectively across various delivery methods.

Regulatory References

What side effects are possible with Doricum (Midazolam)?

Possible Side Effects and Safety Information

The safety profile of Midazolam, the active ingredient in Doricum, is primarily defined by its effects as a central nervous system depressant, as documented in official regulatory labeling.

Common and Expected Adverse Reactions

The most frequently classified adverse reactions involve the Nervous and Respiratory Systems, listed as Very Common or Common in regulatory reports. These effects include sedation, somnolence, decreased respiratory rate, and respiratory depression. Anterograde amnesia (forgetfulness) is also an expected pharmacological effect noted in official documents. Other common reactions may include hypotension (low blood pressure) and nausea.

Serious Adverse Reactions

Official prescribing information highlights the risk of serious cardiorespiratory adverse events, including respiratory arrest and cardiac arrest. Certain psychiatric manifestations, referred to as paradoxical reactions (e.g., hostility, combativeness, agitation), are also officially documented. Furthermore, the development of physical dependence and subsequent withdrawal syndrome are risks associated with prolonged use.

Safety Considerations and Restrictions

Official safety texts specify that the risk of life-threatening cardiorespiratory incidents is documented as more likely to occur when a high dosage is administered. Specific populations require particular caution: older adults and patients with hepatic or renal impairment may experience an increased risk of prolonged effects. A key restriction documented in regulatory labeling concerns the significant risk of enhanced sedation, profound respiratory depression, and coma when used concomitantly with other CNS depressants (e.g., opioids or alcohol).

Overdose and Emergency Response

The official regulatory overdose profile for Midazolam is defined by the risk of severe central nervous system (CNS) and cardiorespiratory compromise, requiring specific emergency interventions.

Documented Overdose Manifestations

Overdose presents as a dose-dependent intensification of the medicine's effects. Clinical signs include excessive sleepiness (somnolence), profound confusion, unsteadiness (ataxia), and slurred speech, potentially leading to loss of consciousness. Respiratory manifestations are noted as slow or shallow breathing (hypoventilation).

Severe Outcomes and Required Actions

Overdosage can lead to life-threatening cardiorespiratory adverse reactions. These severe outcomes include respiratory depression, apnea, airway obstruction, and subsequent respiratory arrest or cardiac arrest, which may result in permanent neurologic injury or death if untreated. Immediate medical attention or emergency help right away is required if any signs of overdose are observed, particularly if breathing slows or stops.

Management and Population Considerations

Management involves providing symptomatic and supportive treatment, focusing on maintaining a patent airway and ensuring the availability of the specific reversal agent flumazenil. Continuous monitoring of respiratory and cardiac function is necessary until the patient is stable. The danger of apnea is greater in elderly patients and those with decreased pulmonary reserve or chronic disease states, such as COPD.

Therapeutic Uses of Doricum (Midazolam)

What Doricum (Midazolam) Treats: Main Uses and Benefits

Doricum (Midazolam) is generally used across therapeutic domains requiring appropriate and short-term symptomatic assistance to manage acute symptomatic episodes and provides supportive comfort. The medication may assist with easing anxiety and supporting temporary memory blunting of events during medical procedures.

“The medication is generally considered relevant across acute therapeutic contexts involving significant symptom expression, often used when short-term symptomatic assistance is needed.”

The medicine is commonly used to help with conditions characterized by periods of heightened symptoms and applied in clinical settings that involve acute or unstable symptom patterns. This support is commonly applied during phases of increased distress, including pre-procedural sedation for minor surgery or diagnostic tests, emergency seizure management, and sustained sedation for patients in intensive care. It plays a role in managing symptoms that interfere with daily comfort, such as profound wakefulness or agitation in critically ill patients, intense apprehension before interventions, and recurrent convulsive seizure activity (status epilepticus). A key benefit is the induction of temporary memory loss (amnesia), which offers symptomatic relief that helps patients cope more steadily with highly distressing clinical phases.

Quick Fact: Support for Acute Apprehension Midazolam is applied in addressing severe pre-procedural anxiety and fear, helping patients achieve a state of calmness that contributes to improved comfort during necessary medical interventions.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Doricum (Midazolam)?

Official regulatory documents define strict eligibility criteria for using Midazolam, based on age, underlying health conditions, and patient status.

Regulatory Eligibility Status	Population Group/Condition
Contraindicated (Must Not Use)	Known hypersensitivity to Midazolam or any benzodiazepine
	Patients with acute narrow-angle glaucoma
	Neonates less than six months of age (for continuous intravenous infusion)
Restricted/Cautionary Use	Older Adults (typically geq60 years of age)
	Patients with severe respiratory insufficiency (e.g., COPD)
	Patients with severe hepatic (liver) impairment
	Use during late stages of pregnancy

Condition-Specific Limitations:

Use is restricted and requires careful consideration in populations with compromised organ function, such as severe renal impairment or congestive heart failure, due to the potential for the medicine's effects to be prolonged. Patients with existing muscle or nerve disorders, such as Myasthenia Gravis, are also restricted populations as use may worsen the condition. For pediatric patients, eligibility is highly dependent on age and the specific route of administration. The use of Midazolam is not recommended near term during pregnancy due to the risk of effects on the newborn. All use in eligible populations requires continuous cardiorespiratory monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Doricum (Midazolam) has clinically significant interactions based on two primary mechanisms: the enhanced effects of Central Nervous System (CNS) depressants and the drug's metabolism by a specific liver enzyme.

1. CNS Depressant Interactions

Concomitant use with other CNS depressants, including opioids (such as morphine or fentanyl), alcohol, other benzodiazepines, barbiturates, and some antipsychotics or sedative antidepressants, can lead to dangerous additive effects. This combination significantly increases the risk of profound sedation, respiratory depression, coma, and potentially death. Close clinical monitoring for signs of slowed or shallow breathing is required if co-administration is necessary.

2. CYP3A4 Enzyme Interactions

Midazolam is primarily broken down in the body by the Cytochrome P450-3A4 (CYP3A4) enzyme. Substances that affect this enzyme alter midazolam's levels and duration of effect:

CYP3A4 Inhibitors (e.g., certain azole antifungals like ketoconazole, some macrolide antibiotics like erythromycin, and HIV/HCV protease inhibitors) decrease midazolam's clearance, which can prolong or deepen its sedative effect. Co-administration with strong inhibitors is generally avoided.
CYP3A4 Inducers (e.g., St John's Wort) may speed up midazolam's metabolism, reducing its effectiveness.

Dietary Restriction: Consumption of grapefruit juice or grapefruit products should be avoided, as they inhibit CYP3A4 and can increase the concentration and effect of midazolam.

Mechanism of Action

Agonism at the GABA-A Receptor

Doricum (Midazolam) functions as an allosteric agonist at the gamma-aminobutyric acid type A ( GABA-A) receptor. This receptor is the primary mediator of fast inhibitory synaptic transmission in the central nervous system. The drug's mechanism centers on enhancing the effects of the endogenous inhibitory neurotransmitter, GABA.

Allosteric Modulation and Chloride Flux

Midazolam binds specifically to the benzodiazepine site, which is situated between the alpha and gamma subunits of the receptor complex. This interaction induces an allosteric modulation of the receptor structure. The key molecular consequence is an increase in the frequency of the chloride ion ( Cl^-) channel opening when GABA is already bound.

Neuronal Hyperpolarization

The increased flux of negatively charged chloride ions into the post-synaptic neuron causes an internal voltage drop, resulting in neuronal hyperpolarization. This physiological process increases the threshold required to generate an action potential, subsequently reducing overall neuronal excitability within the central nervous system.

Dosage and Administration Information

Official Administration Guidelines

Midazolam is a potent, short-acting medicine that requires slow administration and careful individualization of dosage. The administration is governed by the route and the setting of use, often requiring specialist supervision.

Instruction Entity	Regulatory Statement
Route of Administration	Approved routes include Intravenous (IV), Intramuscular (IM), Oral, Oromucosal/Buccal, Rectal, and Intranasal (route depends on the specific product formulation).
Dosing Schedule	IV Sedation (Adults < 60): Initial dose of 2 to 2.5 mg, titrated slowly with 1 mg increments after at least 2 minutes. Total dose usually less than or equal to 5 mg. Continuous IV Infusion: Maintenance rate often 0.02 to 0.10 mg/kg/hr.
Frequency and Timing	Intermittent Use: Subsequent doses must be administered only after a 2 to 3-minute interval has passed to fully assess the initial sedative effect. Acute Use: Single dose only; a second dose is generally administered only after a specific time (e.g., 10 minutes for acute seizures) and often requires medical advice.
Preparation Requirements	IV Solution: Dilution to a concentration of 1 mg/mL is recommended to facilitate a slower, more controlled injection and accurate titration. Rectal Solution: May be diluted with water up to a 10 mL total volume if the prescribed dose volume is too small.
Age-Group Rules	Older Adults (age 60 or older): Require lower initial IV doses (e.g., 0.5 to 1.0 mg) and slower titration; the total dose is typically restricted to less than or equal to 3.5 mg. Neonates: Rapid IV injection is prohibited; continuous infusion is recommended for sedation in this group.
Special Procedural Conditions	IV Administration: Must be performed slowly (e.g., over at least 2 minutes) and never as a rapid bolus. All parenteral use requires a setting where continuous monitoring and resuscitation equipment are immediately available.

This medicine is designed for acute or monitored use, where the dose is always individualized and titrated by a healthcare professional according to the patient's acute needs. Long-term continuous IV use requires the dose to be gradually tapered upon cessation to prevent potential withdrawal reactions.

Recent Clinical Evidence

Research exploring Doricum (Midazolam) is primarily focused on acute and short-term interventions. For acute repetitive seizures, research relies on comparative Randomized Controlled Trials and pre-hospital observational studies. These trials measured the time elapsed until seizure activity cessation and the need for additional rescue medications in emergency settings involving children and adults. Study reports indicate patterns related to the measured cessation of activity within pre-defined time limits, but long-term effects are not fully established regarding subsequent neurological outcomes.

For pre-procedural sedation and anxiety relief, studies explored outcomes related to physical discomfort, including the measured level of patient sedation, the measured change in apprehension, and the evaluation of temporary memory loss (amnesia). The research describes patterns where a targeted sedation level was measured and achieved within short time intervals. However, limited information exists for long-term outcomes regarding potential subtle cognitive changes.

In the Intensive Care Unit (ICU) setting, Doricum was studied for its use in patients requiring continuous sedation and mechanical ventilation. Research reports describe patterns related to the measured achievement and maintenance of targeted levels of sedation. Studies examined outcomes such as the total number of days patients spent on the mechanical ventilator and the incidence of delirium in relation to different sedative agents studied. Comparative evidence is lacking to establish a consistent strategy for adjusting the dose (titration) in relation to potential outcomes monitored.

Studies have explored the medicine’s activity in specific patient populations, including pediatric and older adult groups where sedation or acute seizure management were monitored outcomes. While findings describe patterns related to measured outcomes in these groups, data for certain co-existing conditions remain insufficient. The overarching research gaps highlight that follow-up durations were limited across most studies, and the available data are still emerging when it comes to long-term safety and cognitive outcomes, especially after extended use.

Frequently Asked Questions (FAQ)

Common questions about Doricum (Midazolam) (FAQ)

Q: How quickly is Doricum (Midazolam) generally expected to start working?

Official product information notes that the medicine’s effect is described as rapid, particularly when administered intravenously. Sedation is often reported to begin within a few minutes after the medicine is given.

Q: How long do the effects of Doricum (Midazolam) usually last in the body?

Doricum (Midazolam) is classified as a short-acting medicine. Official sources indicate that its plasma half-life—the time it takes for the amount of drug in the body to be cut in half—is typically between 1.5 and 2.5 hours in healthy adults.

Q: Can Doricum (Midazolam) be used in children for sedation?

Regulatory documents confirm that Midazolam is officially indicated for sedation in children. This use often occurs for specific pre-operative situations or during diagnostic procedures. The official dosing guides include specific age and dose restrictions tailored to the pediatric population.

Q: Does Doricum (Midazolam) have a 'black box warning' in the United States?

Yes, the official US labeling for this medicine includes a Boxed Warning. This warning is intended to highlight the significant risks of profound sedation and severe respiratory depression (slowed breathing). The concern is specifically emphasized when the medicine is used at the same time as opioid medicines.

Q: Is it possible to develop a tolerance to the effects of Doricum (Midazolam)?

Official product documents indicate that a degree of tolerance to the effects of Doricum (Midazolam) is possible. Tolerance is when the body needs a higher dose over time to achieve the same effect. This pattern is generally discussed in the context of repeated, prolonged administration.

Q: Is Doricum (Midazolam) known to be safe to use during pregnancy or while breastfeeding?

Regulatory documents caution that use of Midazolam is generally not recommended during the late stage of pregnancy because of documented risks to the fetus. Official information also indicates that the drug's active substance passes into breast milk in small amounts.

Q: Is it true that Doricum (Midazolam) can cause confusion or agitation?

Yes, official documents list the potential for psychiatric and paradoxical reactions as documented adverse reactions. These effects can include feelings of agitation, confusion, or hostility.

Q: Do official sources discuss the potential for misuse of Doricum (Midazolam)?

Midazolam is classified as a Schedule IV controlled substance by US regulatory authorities. Official labeling describes the potential for both dependence and abuse upon prolonged or non-indicated use.

Q: Why is Doricum (Midazolam) considered an essential medicine by some health organizations?

Midazolam is included on the World Health Organization (WHO) Essential Medicines List. This inclusion reflects its established utility as a sedative and its documented role in managing acute and repetitive seizures globally.

Q: What is the significance of the half-life of Doricum (Midazolam)?

The short elimination half-life of the medicine heavily influences its clinical properties. This half-life is cited in regulatory documents as contributing to its rapid onset and short overall duration, which makes it commonly used for acute, brief medical interventions.

Q: What is the difference in purpose between Doricum (Midazolam) and Diazepam (Valium)?

Midazolam is often distinguished from longer-acting medicines in the same class, such as Diazepam. Official information notes that Doricum (Midazolam) has a significantly faster onset and a shorter half-life. This profile results in its use being focused on acute, short-term sedation, distinguishing it from medicines intended for longer-term applications.

Q: Is it normal to feel drowsy for a long time after Doricum (Midazolam)?

Somnolence, or drowsiness, is listed as a very common side effect in official documents. While the medicine is short-acting, regulatory information cautions that older adults or patients with pre-existing kidney or liver impairment may experience a more prolonged sedative effect than others.

Q: Is Doricum (Midazolam) typically used as a sleep aid outside of hospital settings?

The official indications for Doricum (Midazolam) are for sedation and anxiety relief related to medical procedures or acute situations. It is not indicated by regulatory bodies for general, long-term use as an insomnia sleep aid.

Q: What are the general expectations about recovery time after receiving Doricum (Midazolam) for a procedure?

Regulatory guidelines stress the need for patient monitoring until full recovery from sedation is confirmed, given the medicine’s short-acting nature. Patients are typically advised in official documentation to avoid resuming complex tasks, such as driving, until the sedative effects have completely worn off.

Q: Does the form of Doricum (Midazolam) (e.g., liquid vs. tablet) change the side effects?

The general side effect profile is related to the active substance, Midazolam, and is consistent across forms. However, the specific route of administration (such as injection versus oral) may influence the frequency or severity of local reactions at the site of administration, as documented in official reports.

Q: Is Doricum (Midazolam) used for pain management?

The primary pharmacological properties of Doricum (Midazolam) are described as sedative, anxiolytic, and hypnotic. Official indications do not list the medicine as an analgesic, meaning it is not indicated for the purpose of pain management.

Q: Does Doricum (Midazolam) affect a person's ability to drive or operate machinery?

Official product information includes an explicit warning that the drug can seriously impair a person's ability to drive or operate complex machinery. This warning is due to its powerful sedative effects, which can significantly reduce alertness and reaction time.

Q: Can I use Doricum (Midazolam) if I have a history of depression?

Regulatory labeling for medicines in this class advises caution regarding use in patients with a history of depressive states or suicidal tendencies. Official reports indicate the potential for them to sometimes precipitate or worsen symptoms in this population.

Q: Are there specific symptoms that warrant immediate medical attention after receiving Doricum (Midazolam)?

Official patient information leaflets detail specific serious adverse reactions that require immediate medical assistance. These symptoms commonly include, but are not limited to, severe difficulty breathing, indications of a severe allergic reaction, or signs of heart problems.

Q: Is the use of Doricum (Midazolam) limited to hospital environments only?

While Midazolam is frequently used in monitored settings, its use is not limited exclusively to hospitals. Regulatory authorities have approved certain formulations, such as those for acute seizure management, for use in out-of-hospital or home settings under specific circumstances.

How should Doricum (Midazolam) be stored and disposed of?

How to Store and Dispose of Doricum (Midazolam)

Official regulatory guidelines mandate specific storage and disposal procedures for Midazolam, a controlled substance, to maintain its stability and ensure public safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, 20^circ to 25 C (68^circ to 77 F).
Protection	Keep protected from light and away from excess moisture and heat.
Container	Keep the medicine in its original container, tightly closed.
Integrity	Do not use the injection if visible precipitation or crystallization is present.

Disposal Instructions

Disposal must be consistent with State and Federal Controlled Substance Regulations. The medicine must be kept out of sight and reach of children at all times. The preferred method for disposal of unused or expired product is through a drug take-back program. If a take-back program is unavailable, the FDA advises that this medicine may be flushed down the toilet to prevent accidental ingestion and serious harm.

Doricum (Midazolam)